Suresh S Ramalingam

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi request reprint Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:3605-10. 2007
  2. ncbi request reprint Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database
    Taofeek K Owonikoko
    Emory Winship Cancer Institute, 1365 Clifton Rd, Ste C 5090, Atlanta, GA 30322, USA
    J Clin Oncol 25:5570-7. 2007
  3. doi request reprint Advances in the diagnosis and treatment of non-small cell lung cancer
    Rathi N Pillai
    Corresponding Author Suresh S Ramalingam, 1365 Clifton Road NE, Room C 3090, Atlanta, GA 30322
    Mol Cancer Ther 13:557-64. 2014
  4. doi request reprint Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
    Suresh S Ramalingam
    Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, Suite C 3090, Atlanta, GA 30322, USA
    J Clin Oncol 30:3337-44. 2012
  5. pmc Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, Atlanta, GA 30322, USA
    J Clin Oncol 28:4507-12. 2010
  6. doi request reprint The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Oncologist 14:412-24. 2009
  7. pmc Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA
    J Thorac Oncol 4:97-101. 2009
  8. pmc Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, 1365 Clifton Rd, C 3090, Atlanta, GA 30322, USA
    J Clin Oncol 28:56-62. 2010
  9. pmc Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504)
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, Atlanta, GA, USA
    J Clin Oncol 29:1709-14. 2011
  10. pmc Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003)
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
    J Thorac Oncol 6:1741-5. 2011

Detail Information

Publications62

  1. ncbi request reprint Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:3605-10. 2007
    ..The primary objective of this study was to determine the recommended phase II doses of the novel histone deacetylase inhibitor vorinostat when administered in combination with carboplatin and paclitaxel...
  2. ncbi request reprint Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database
    Taofeek K Owonikoko
    Emory Winship Cancer Institute, 1365 Clifton Rd, Ste C 5090, Atlanta, GA 30322, USA
    J Clin Oncol 25:5570-7. 2007
    ..To study the burden and outcome of lung cancer in the elderly, particularly for patients aged 80 years and older...
  3. doi request reprint Advances in the diagnosis and treatment of non-small cell lung cancer
    Rathi N Pillai
    Corresponding Author Suresh S Ramalingam, 1365 Clifton Road NE, Room C 3090, Atlanta, GA 30322
    Mol Cancer Ther 13:557-64. 2014
    ..Emerging technological advances and greater insights into tumor biology are poised to greatly reduce the burden of lung cancer in the years to come...
  4. doi request reprint Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
    Suresh S Ramalingam
    Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, Suite C 3090, Atlanta, GA 30322, USA
    J Clin Oncol 30:3337-44. 2012
    ....
  5. pmc Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, Atlanta, GA 30322, USA
    J Clin Oncol 28:4507-12. 2010
    ..We conducted a phase I study to determine the maximum-tolerated dose and pharmacokinetics of vorinostat in patients with hepatic dysfunction...
  6. doi request reprint The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Oncologist 14:412-24. 2009
    ..In addition to the available evidence, prospective evaluation of novel agents in elderly-specific or -enriched studies is necessary to guide the treatment of older patients with NSCLC...
  7. pmc Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA
    J Thorac Oncol 4:97-101. 2009
    ..This class of compounds has demonstrated anticancer activity in malignant mesothelioma. We conducted a phase II study of belinostat in patients with relapsed malignant pleural mesothelioma...
  8. pmc Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, 1365 Clifton Rd, C 3090, Atlanta, GA 30322, USA
    J Clin Oncol 28:56-62. 2010
    ..CONCLUSION Vorinostat enhances the efficacy of carboplatin and paclitaxel in patients with advanced NSCLC. HDAC inhibition is a promising therapeutic strategy for treatment of NSCLC...
  9. pmc Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504)
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, Atlanta, GA, USA
    J Clin Oncol 29:1709-14. 2011
    ..We conducted a phase II study to evaluate cetuximab for the treatment of advanced BAC...
  10. pmc Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003)
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
    J Thorac Oncol 6:1741-5. 2011
    ..Bortezomib, a proteasome inhibitor, has demonstrated objective responses in patients with BAC in early-phase clinical trials. We conducted a phase II study of bortezomib in patients with advanced-stage BAC...
  11. doi request reprint Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer
    Suresh S Ramalingam
    Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    J Clin Oncol 29:4574-80. 2011
    ..The strong preclinical evidence supporting coinhibition of IGF-1R and epidermal growth factor receptor (EGFR) as anticancer therapy prompted this study...
  12. ncbi request reprint A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
    Suresh S Ramalingam
    Authors Affiliations Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 14:3456-61. 2008
    ..We conducted a phase I study in patients with advanced malignancies to determine the recommended phase II dose of the combination of 17-AAG and paclitaxel...
  13. doi request reprint Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
    J Clin Oncol 26:60-5. 2008
    ..We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients...
  14. pmc Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Thorac Oncol 5:1279-84. 2010
    ..We evaluated the safety and efficacy of cediranib, a potent small molecule inhibitor of the vascular endothelial growth factor receptor, in patients with refractory or recurrent small cell lung cancer (SCLC)...
  15. pmc The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo
    Hui Ren
    Department of Respiration, First Affiliated Hospital of Medical College of Xi an Jiaotong University, Shaanxi, PR China
    Cancer Lett 325:139-46. 2012
    ..Collectively, we suggest that the combination of RAD001 and BKM120 may be an effective regimen for treatment of lung cancer, hence warranting further evaluation of the combination in the clinic...
  16. pmc Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation
    Yikun Li
    Departments of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia 30322, USA
    J Biol Chem 288:13215-24. 2013
    ..The mechanisms underlying rapamycin-induced Akt phosphorylation have not been fully elucidated...
  17. pmc Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells
    Taofeek K Owonikoko
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Int J Cancer 126:743-55. 2010
    ..This likely involves a vorinostat-mediated irreversible increase in DNA damage in the case of carboplatin and a reversible increase in microtubule stability in the case of paclitaxel...
  18. pmc Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University, Winship Cancer Institute, 1365 Clifton Road NE, Atlanta, GA 30322, USA
    J Thorac Oncol 8:369-72. 2013
    ..01) but not with progression-free survival or overall survival. The combination of everolimus and docetaxel was tolerated well, but the efficacy was relatively modest in an unselected population of patients with NSCLC...
  19. pmc Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia 30322, USA
    Cancer 116:3903-9. 2010
    ..The authors conducted a phase 1 and pharmacokinetic study of everolimus and docetaxel for recurrent NSCLC...
  20. pmc Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis
    Taofeek K Owonikoko
    Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia 30322, USA
    Oncologist 18:600-10. 2013
    ..This study assessed the real-world effectiveness of cytotoxic agents that became available for the treatment of non-small cell lung cancer (NSCLC) in the last 2 decades...
  21. ncbi request reprint Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study
    Chandra P Belani
    Department of Medicine, Penn State Hershey Medical Center, Penn State Cancer Institute, Hershey, Pennsylvania 17033 0850, USA
    Cancer 113:2512-7. 2008
    ..Therefore, a phase 2 study was conducted to evaluate the efficacy of the combination of cetuximab, carboplatin, and docetaxel for the treatment of advanced NSCLC...
  22. pmc Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy
    Cheng Xiong Xu
    Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA
    Cancer Biol Ther 12:549-55. 2011
    ..Thus, induction of autophagy by BEZ235 appears to be a survival mechanism that may counteract its anticancer effects. Based on these, we suggest a strategy to enhance BEZ235's anticancer efficacy by blockade of autophagy...
  23. pmc Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer
    Rui Li
    Corresponding Author Xingming Deng, Division of Cancer Biology, Department of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322
    Mol Cancer Ther 12:2200-12. 2013
    ..These findings uncover a novel mechanism of erlotinib resistance and provide a novel approach to overcome resistance by blocking the STAT3/Bcl2/Bcl-XL survival signaling pathway in human lung cancer...
  24. pmc Novel small-molecule inhibitors of Bcl-XL to treat lung cancer
    Dongkyoo Park
    Departments of Radiation Oncology, Hematology and Medical Oncology, and Pathology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
    Cancer Res 73:5485-96. 2013
    ..BXI-72 overcomes acquired radioresistance of lung cancer. On the basis of our findings, the development of BXI(s) as a new class of anticancer agents is warranted and represents a novel strategy for improving lung cancer outcome...
  25. pmc A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer
    Taofeek K Owonikoko
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Thorac Oncol 7:866-72. 2012
    ..Potential differences in the efficacy of second-line therapy for refractory and sensitive SCLC have not been well studied...
  26. pmc Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
    Ramesh K Ramanathan
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Oncol 28:1520-6. 2010
    ..To define the maximum tolerated dose, toxicities, pharmacokinetics, and pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG)...
  27. pmc Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer
    Yikun Li
    Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA
    Cancer Biol Ther 13:272-80. 2012
    ..Taken together, we suggest that elevated eIF4E in NSCLC cells is associated with proliferation, invasion and acquired erlotinib resistance...
  28. pmc The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo
    Cheng Xiong Xu
    Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia, United States of America
    PLoS ONE 6:e20899. 2011
    ..Taken together, our results suggest that the combination of RAD001 and BEZ235 is a novel strategy for cancer therapy...
  29. doi request reprint Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women
    Seema Harichand-Herdt
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA
    Semin Oncol 36:572-80. 2009
    ..This article reviews the gender-related differences in clinical and pathologic factors and outcomes of patients with lung cancer observed in population-based studies and clinical trials...
  30. pmc A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Hum Gene Ther 22:336-42. 2011
    ..There were no dose-limiting toxicities reported in all three dosing tiers. It is concluded that the oral administration of MnSOD PL is feasible and safe. The phase II recommended dose is 30 mg...
  31. doi request reprint Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus
    Taofeek K Owonikoko
    Emory University Winship Cancer Institute, Atlanta, Georgia, USA
    Clin Cancer Res 16:2496-504. 2010
    ..This article reviews recent data with maintenance therapy in advanced NSCLC and discusses the implications for routine patient care and future drug development...
  32. doi request reprint E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer
    Taofeek K Owonikoko
    Emory University, Atlanta, GA, USA
    Cancer Chemother Pharmacol 73:171-80. 2014
    ..Sequence-dependent improved efficacy of topoisomerase I followed by topoisomerase 2 inhibitors was assessed in a randomized phase II study in extensive-stage small-cell lung cancer (SCLC)...
  33. doi request reprint Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung cancer
    Bree R Eaton
    Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
    Cancer 119:3753-60. 2013
    ....
  34. doi request reprint Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor
    Seema Harichand-Herdt
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA
    Semin Thorac Cardiovasc Surg 20:217-23. 2008
    ..This article reviews the role of currently available and emerging EGFR inhibitors in the treatment of NSCLC...
  35. pmc Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies
    John Kauh
    Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia, USA
    Cancer 117:4049-59. 2011
    ..This pilot study evaluated the biological effects of LNF and docetaxel (DTX) combination therapy in refractory solid tumors by comparing pretreatment and post-treatment tumor biopsies...
  36. ncbi request reprint Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): A systematic review
    Madhusmita Behera
    Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, United States Winship Cancer Institute of Emory University, Atlanta, GA, United States
    Oral Oncol 50:888-94. 2014
    ..We conducted a systematic review of published clinical trials of taxane-containing versus standard non-taxane-based regimens used in definitive treatment of SCCHN...
  37. pmc Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer
    Taofeek K Owonikoko
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Cancer 119:1503-11. 2013
    ..For this study, the authors assessed the association of cellular-based and serum-based immunologic mediators with thyroid cancer recurrence...
  38. ncbi request reprint Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables
    Madhusmita Behera
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Clin Lung Cancer 14:128-38. 2013
    ..Lung cancer is the leading cause of cancer-related mortality. Understanding patient attributes that enhance survival and predict recurrence is necessary to individualize treatment options...
  39. pmc Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy
    Xuerong Wang
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Biol Ther 7:1952-8. 2008
    ..Thus, we suggest a therapeutic strategy for enhancing mTOR-targeted cancer therapy by preventing mTOR inhibition-induced feedback activation of several survival mechanisms...
  40. pmc Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis
    Madhusmita Behera
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, Atlanta, GA, USA
    Lung Cancer 77:331-8. 2012
    ..Maintenance therapy is a new treatment paradigm for advanced non-small cell lung cancer (NSCLC). We conducted a meta-analysis of randomized studies with single agent maintenance therapy...
  41. pmc Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions
    Rossella Marullo
    Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, United States of America Department of Medical Oncology, University of Messina, Messina, Italy
    PLoS ONE 8:e81162. 2013
    ..This study provides a new mechanistic insight into cisplatin-induced cell killing and may lead to the design of novel therapeutic strategies to improve anticancer drug efficacy. ..
  42. pmc Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues
    Songqing Fan
    Department of Hematology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer Biol Ther 8:1463-9. 2009
    ..05). Collectively, these findings suggest that p-eIF4E may play a critical role in cancer development, particularly early stages of tumorigenesis and support p-eIF4E as a good cancer therapeutic target...
  43. doi request reprint Lung cancer: New biological insights and recent therapeutic advances
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA
    CA Cancer J Clin 61:91-112. 2011
    ..This article reviews the major strides made in the treatment of lung cancer in the recent past...
  44. doi request reprint Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy
    Suchita Pakkala
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA
    Clin Lung Cancer 10:S17-23. 2009
    ..Another novel agent, XL647, has demonstrated promising single-agent activity in patients who have been resistant to previous anti-EGFR therapy. Further evaluation of combined EGFR and VEGF inhibition is under investigation...
  45. pmc Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer
    Seth A Brodie
    Atlanta VAMC, Winship Cancer Institute, Atlanta, GA 30322
    Cancer Prev Res (Phila) 7:351-61. 2014
    ..In summary, our study provides evidence for an important role of class I HDACs in controlling the stability of DNMT1 and suggests that HDAC inhibition could be an attractive approach for lung cancer chemoprevention...
  46. pmc c-Myc suppression of DNA double-strand break repair
    Zhaozhong Li
    Department of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Neoplasia 14:1190-202. 2012
    ....
  47. pmc Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy
    Suchita Pakkala
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, USA
    Cancer 118:164-72. 2012
    ..Because highly active antiretroviral therapy (HAART) has improved the survival of patients with human immunodeficiency virus (HIV), the authors evaluated lung cancer outcomes in the HAART era...
  48. ncbi request reprint The role of cetuximab in the management of non-small-cell lung cancer
    Taofeek K Owonikoko
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA
    Clin Lung Cancer 10:230-8. 2009
    ..This article reviews the clinical data with cetuximab in NSCLC...
  49. doi request reprint Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
    Cancer 116:1344-9. 2010
    ..Irinotecan and paclitaxel are active as single agents and exhibit preclinical synergy in SCLC cell lines. A phase 2 study was conducted to evaluate this combination in patients with recurrent or refractory SCLC...
  50. ncbi request reprint Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)
    Rathi N Pillai
    Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Cancer Chemother Pharmacol 74:177-83. 2014
    ..We conducted a phase II study to evaluate if modulation of Bcl-2 with 13-cis-retinoic acid (13-CRA) and interferon alpha could improve response rates when combined with paclitaxel in patients with recurrent SCLC...
  51. doi request reprint The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation
    Rathi N Pillai
    Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, USA
    Curr Oncol Rep 14:105-10. 2012
    ..This article reviews the characteristics, treatment, and ongoing research in patients with ALK-positive NSCLC...
  52. pmc CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC
    Rathi N Pillai
    Department of Hematology and Oncology, Emory University, Atlanta, Georgia 30322, USA
    Clin Cancer Res 19:1603-11. 2013
    ....
  53. pmc Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data
    Madhusmita Behera
    Department of Hematology and Medical Oncology, Emory University, Winship Cancer Institute, 1365 Clifton Road NE, Rm C 3090, Atlanta, GA 30322, USA
    Biomed Eng Online 10:97. 2011
    ..Statistical learning (SL) techniques can address non-linear relationships and small datasets but do not provide an output that has an epidemiologic interpretation...
  54. doi request reprint Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, Atlanta, Georgia, USA
    Curr Opin Oncol 22:79-85. 2010
    ..This review will provide the relevant interventions targeted against specific angiogenesis pathways with or without known effective therapies for nonsmall cell lung cancer (NSCLC)...
  55. ncbi request reprint Recent advances in the treatment of malignant pleural mesothelioma
    Suresh S Ramalingam
    Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, USA
    J Thorac Oncol 3:1056-64. 2008
    ..It is hoped that the HDAC inhibitors and other novel targeted agents will pave the way for improved outcomes for patients with this disease...
  56. pmc Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression
    Latha Dhandapani
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
    Cancer Res 71:5245-54. 2011
    ..Taken together, our findings establish that ATRA accentuates TRAIL-induced apoptosis, reveal a novel mechanism by which retinoids modulate apoptosis, and suggest a novel strategy to augment the anti-cancer activity of TRAIL...
  57. pmc Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck
    Nabil F Saba
    Department of Hematology and Medical Oncology, The Winship Cancer Institute, Emory University, 1365 Clifton Rd, Building C, Atlanta, GA, 30322, USA
    Head Neck Pathol 8:66-72. 2014
    ..There was an observed trend correlating AT with presence nodal metastases. The observed inverse correlation with response to taxane based chemotherapy needs validation in a larger sample size...
  58. pmc Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases
    Qi Qi
    Department of Pathology and Laboratory Medicine, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Biol Chem 287:6113-27. 2012
    ..Hence, combinatorial inhibition of EGFR and PKCs might provide proof of concept in developing therapeutic agents for treating malignant glioma and other human cancers...
  59. doi request reprint Lung cancer in HIV-positive patients
    Suchita Pakkala
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, USA
    J Thorac Oncol 5:1864-71. 2010
    ..This article reviews the impact of HIV on the incidence, risk factors, clinical presentation, and treatment of lung cancer...
  60. ncbi request reprint Second-generation ALK inhibitors: filling the non "MET" gap
    Suresh S Ramalingam
    Authors Affiliation Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia
    Cancer Discov 4:634-6. 2014
    ..Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. These agents now provide new options for the management of ALK-positive NSCLC...
  61. doi request reprint Heat shock protein 90 inhibitors in non-small-cell lung cancer
    Rathi N Pillai
    Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
    Curr Opin Oncol 26:159-64. 2014
    ..This review discusses recent developments in the strategy of Hsp90 inhibition as a targeted therapy in non-small-cell lung cancer (NSCLC)...
  62. doi request reprint Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results
    Primo N Lara
    Clin Lung Cancer 9:141-3. 2008